… in melanoma patients or in drug-sensitivity testing. Therefore, Pgp cannot be regarded as
a major common feature mediating drug resistance in human melanoma cells.10 …

… However, as in BRAF inhibitor monotherapy, resistance develops in most melanoma patients,
and great efforts have been invested to understand how and when tumours resist or stop …

… Cancer chemotherapy efficacy is frequently impaired by either intrinsic or acquired tumor
resistance, a phenomenon termed multi-drug resistance (MDR) [10]. MDR can result from …

… to chemotherapy in melanoma patients or drug-sensitivity testing. Therefore, Pgp cannot be
regarded as a major common feature mediating drug resistance in human melanoma cells (…

… in melanoma patients nor in drug-sensitivity testing could be detected. Therefore Pgp cannot
be regarded as a major common feature mediating drug resistance in human melanoma …

… offers new potential therapeutic targets that alone, or in combination with conventional
cytotoxic drugs, may improve prognosis for melanoma patients with advanced disease. …

… estimated 7,230 melanoma patients will die … patients. In this review, we survey the latest
findings in mechanisms of primary resistance to therapy, with a special emphasis on melanoma …

… of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib
… in melanoma maintenance 3,4 . However, as most patients relapse with lethal drug-resistant …

… patients with advanced BRAF+MEK inhibitor-resistant melanoma, we find that vorinostat can
selectively ablate drug… four resistance mutations commonly found in melanoma patients that …

… (24) Here we present new results that directly validate the role of fibroblasts in melanoma
drug resistance and use these results to motivate a theoretical investigation of different …